Lion biotech formerly genesis biophrama, extremely impressive T-Cell regulation and checkpoint inhibtors. Intelligent opinion only please?.
One of the most notable small companies that is testing this approach might be Lion Biotechnologies (OTCPK:LBIO) helmed by Dr. Manish Singh. Singh was formerly the CEO of ImmunoCellular Therapeutics (IMUC) and made famous his multiple-antigen targeting approach at a time when immunotherapy was stealing the biotechnology spotlight. ImmunoCellular's ICT-107 has produced the best results ever seen in fighting glioblastoma multiforme, more than doubling overall survival in terms of months, and did so by targeting the cancer from several angles, targeting six different antigens expressed by the disease, versus the targeting of one antigen by other immunotherapies (i.e. Provenge).
Now at Lion, one of Singh's top priorities is to take its product, TILs (tumor-infiltrating lymphocytes), and combine it with anti-PD-1s. Already in a Phase 2 study on patients with the severest and most deadly form of melanoma, TILs produced a 22% complete response, and 19 of the 20 patients who achieved a complete response are still alive 6-9 years later. In a study of 136 patients treated at NCI, MD Anderson and other top institutions, TILs produced a 50% objective response, which is far better than any other FDA approved late-stage melanoma treatment, a second and third line salvage setting where all other treatments had failed.
While the Phase 2 data was very good, Singh now looks to test TILs with anti-PD-1s and other therapeutics such as Zelboraf. According to clinicaltrials.gov, the Phase 1 study for TILs and Zelboraf is actively recruiting patients. Zelboraf is a highly effective treatment for melanoma patients who have a BRAF mutation, but unfortunately, patients often recur within 9 months of treatment. Thus, by combining two different treatment approaches (TILs and Zelboraf) it is possible to keep those patients in a disease free state for longer periods of time. It is this thought process of using different therapeutic approaches that Bristol-Myers, Merck, AstraZeneca, and even sm
Neshua, I'll check out LBIO, thanks. Have a look at SNTI...they're going to have a presentation next month also
regarding melanoma. And their market value less than 10m, so I envision great potential for them (I've very small position).
It looks like another NWBO or DNDN...meaning, the manufacturing will be too costly to make it a viable product for sale. You will also notice that CLDX, I believe, generally posts both efficacy and safety....because both are required for drug approval. I did not see any safety information on their product...which is not a good sign. If safety is fine, then they should announce it...they are hiding something.
CLDX R+D, Manufacturing, and Marketing (soon) are good to go.